Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53

Inotuzumab ozogamicin (IO) is an anti-CD22 calicheamicin immunoconjugate that has been recently approved for the treatment of relapsed or refractory B-Acute Lymphoblastic Leukemia (r/r B-ALL). We employed both immortalized and primary cells derived from CD22-positive lymphoproliferative disorders to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tirrò, Elena, Massimino, Michele, Romano, Chiara, Pennisi, Maria Stella, Stella, Stefania, Vitale, Silvia Rita, Fidilio, Annamaria, Manzella, Livia, Parrinello, Nunziatina Laura, Stagno, Fabio, Palumbo, Giuseppe Alberto, La Cava, Piera, Romano, Alessandra, Di Raimondo, Francesco, Vigneri, Paolo G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387953/
https://www.ncbi.nlm.nih.gov/pubmed/30834235
http://dx.doi.org/10.3389/fonc.2019.00057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387953/
https://www.ncbi.nlm.nih.gov/pubmed/30834235
http://dx.doi.org/10.3389/fonc.2019.00057

Ejemplares similares